The KEEPS-cognitive and affective study: Baseline associations between vascular risk factors and cognition

Journal of Alzheimer's Disease

Volumn 40, Issue 2, 2014, Pages 331-341

  Wharton, Whitney ^a,b   Gleason, Carey E ^c,d   Dowling, N Maritza ^c   Carlsson, Cynthia M ^c,d   Brinton, Eliot A ^e   Santoro, M Nanette ^f   Neal Perry, Genevieve ^g   Taylor, Hugh ^h   Naftolin, Frederick ⁱ   Lobo, Rogerio A ^j   Merriam, George ^k   Manson, Joann E ^l   Cedars, Marcelle I ^m   Miller, Virginia M ⁿ   Black, Dennis M ^m   Budoff, Matthew ^o   Hodis, Howard N ^p   Harman, S Mitchell ^q   Asthana, Sanjay ^c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NEW YORK UNIVERSITY   (United States)

^j New York Presbyterian Columbia University Medical Center   (United States)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ MAYO CLINIC   (United States)

^o LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^p UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^q CARL T HAYDEN VA MEDICAL CENTER   (United States)

more..

Author keywords

Attention; blood pressure; clinical trial; cognition; estradiol; estrogen; hormone therapy; memory; vascular risk

Indexed keywords

ESTRADIOL; ESTRONE; PROGESTERONE; TESTOSTERONE; ESTROGEN; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATTENTION; AUDITORY MEMORY; CARDIOVASCULAR RISK; COGNITION; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; MENTAL PERFORMANCE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEX HORMONE DETERMINATION; SYSTOLIC BLOOD PRESSURE; TASK PERFORMANCE; TESTOSTERONE BLOOD LEVEL; WORKING MEMORY; BLOOD; BLOOD PRESSURE; COGNITION DISORDERS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INTRADERMAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; MOOD DISORDERS; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ATTENTION; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COGNITION DISORDERS; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGENS; FEMALE; HORMONES; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS;

EID: 84901949958     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130245     Document Type: Article

References (52)

1. Berent-Spillson A, Persad CC, Love T, Sowers M, Randolph JF, Zubieta JK, Smith YR (2012) Hormonal environment affects cognition independent of age during the menopause transition. J Clin Endocrinol Metab 97, E1686-E1694.
2. Weber M, MapstoneM(2009) Memory complaints and memory performance in the menopausal transition. Menopause 16, 694-700.
3. Bagger YZ, Tanko LB, Alexandersen P, Qin G, ChristiansenC (2005) Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 12, 12-17.
4. Sherwin BB (2012) Estrogen and cognitive functioning in women: Lessons we have learned. Behav Neurosci 126, 123- 127.
5. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, SagaraY, TaketaniY, Orimo H, OuchiY(1995) Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92, 3431-3435.
6. Kivipelto M, Helkala EL, Laakso MP, H?anninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137, 149-155. (Pubitemid 34827510)
7. Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M, Sasaki H (2004) Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 52, 649-650. (Pubitemid 38480653)
8. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM (2011) Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26, 699-708.
9. Kehoe PG, Davies NM, Martin RM, Ben-Shlomo Y (2013) Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 33, 999-1008.
10. in't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM (2001) Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 22, 407-412. (Pubitemid 32510912)
11. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M,WagsterMV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
12. Weber MT, Mapstone M, Staskiewicz J, Maki PM (2012) Reconciling subjective memory complaints with objective memory performance in the menopausal transition. Menopause 19, 735-741.
13. Maric-Bilkan C, Manigrasso MB (2012) Sex differences in hypertension: contribution of the Renin-Angiotensin system. Gender Med 9, 287-291.
14. Jefferson AL (2010) Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis 20, 813-821.
15. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 322, 1447-1451. (Pubitemid 32575406)
16. Wharton W, Hirshman E, Merritt P, Stangl B, Scanlin K, Krieger L (2006) Lower blood pressure correlates with poorer performance on visuospatial attention tasks in younger individuals. Biol Psychol 73, 227-234. (Pubitemid 46053651)
17. Knecht S,Wersching H, Lohmann H, Bruchmann M, Duning T, Dziewas R, Berger K, Ringelstein EB (2008) High-normal blood pressure is associated with poor cognitive performance. Hypertension 51, 663-668. (Pubitemid 351301518)
18. Elias PK, Elias MF, Robbins MA, Budge MM (2004) Blood pressure-related cognitive decline: Does age make a difference? Hypertension 44, 631-636. (Pubitemid 39435231)
19. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N (2005) KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8, 3-12. (Pubitemid 40675116)
20. Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM (2012) The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis 32, 147-156.
21. Budoff MJ, Chen GP, Hunter CJ, Takasu J, Agrawal N, SorochinskyB,MaoS (2005) Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. J Womens Health 14, 410-417. (Pubitemid 41052039)
22. Teng EL, Chui HC (1987) The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 48, 314-318. (Pubitemid 17138128)
23. Wilson JR, Cockburn J, Baddeley A (1985) The Rivermead Behavioural Memory Test, Thames Valley Test Company.
24. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B (1999) Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol 12, 168- 179. (Pubitemid 30072300)
25. Golden C (1978) The Stroop Color and Word Test: A manual for clinical and experimental uses, Stoetling, Chicago.
26. WechslerD(1997)Wechsler Memory Scales-3rd Edition, The Psychological Corporation, San Antonio, TX.
27. WechslerD(1991)WAIS-RWechsler adult intelligence scale- III, Psychological Corporation, New York.
28. Spreen O, Strauss E (1998) A compendium of neuropsychological tests, Oxford University Press, New York.
29. Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California Verbal Learning Test-II, The Psychological Corporation, San Antonio, Texas.
30. Benton A (1974) Revised Visual Retention Test Manual, Psychological Corp, New York.
31. Haasl RJ, Ahmadi MR, Meethal SV, Gleason CE, Johnson SC, Asthana S, Bowen RL, Atwood CS (2008) A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E epsilon4 allele. BMC Med Genet 9, 37.
32. Niu W, Qi Y, Qian Y, Gao P, Zhu D (2009) The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphisms and hypertension: A meta-analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res 32, 1060-1066.
33. Dowling NM, Gleason CE, Manson JE, Hodis HN, Miller VM, Brinton EA, Neal-Perry G, Santoro MN, Cedars M, Lobo R, Merriam GR, Wharton W, Naftolin F, Taylor H, Harman SM, Asthana S (2013) Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance. PLoS One 8, e68741.
34. Browne MW, Cudeck R (1993) Alternative ways of assessing model fit. In Testing Structural Equation Models, Bollen KA, Long JS, eds. Sage Publications, Newbury Park, pp. 136-162.
35. Hochberg Y (1988) A sharper Bonferroni procedure for multiple significance testing. Biometrika 75, 800-803.
36. Brady CB, Spiro A, 3rd, Gaziano JM (2005) Effects of age and hypertension status on cognition: The veterans affairs normative aging study. Neuropsychology 19, 770-777. (Pubitemid 41803523)
37. Launer LJ, Masaki K, Petrovitch H, FoleyD,Havlik RJ (1995) The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 274, 1846-1851. (Pubitemid 26001260)
38. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145. (Pubitemid 126512042)
39. Goldstein FC, Ashley AV, Freedman LJ, Penix L, Lah JJ, Hanfelt J, Levey AI (2005) Hypertension and cognitive performance in African Americans with Alzheimer disease. Neurology 64, 899-901. (Pubitemid 40316335)
40. Madden DJ, Blumenthal JA (1998) Interaction of hypertension and age in visual selective attention performance. Health Psychol 17, 76-83. (Pubitemid 28269773)
41. Elias PK, EliasMF, D'Agostino RB, Cupples LA,WilsonPW, Silbershatz H,Wolf PA (1997) NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 20, 1388-1395. (Pubitemid 27366813)
42. Kovacs KR, Szekeres CC, Bajko Z, Csapo K, Molnar S, Olah L, Magyar MT, Bereczki D, Kardos L, Soltesz P, Bojtor AB, Csiba L (2010) Cerebro- and cardiovascular reactivity and neuropsychological performance in hypertensive patients. J Neurol Sci 299, 120-125.
43. Blumenthal JA, Madden DJ, Pierce TW, Siegel WC, Appelbaum M (1993) Hypertension affects neurobehavioral functioning. Psychosom Med 55, 44-50.
44. Peng N, Clark JT, Prasain J, Kim H, White CR, Wyss JM (2005) Antihypertensive and cognitive effects of grape polyphenols in estrogen-depleted, female, spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 289, R771-R775. (Pubitemid 41208442)
45. Lin J, Kroenke CH, Epel E, Kenna HA, Wolkowitz OM, Blackburn E, RasgonNL(2011) Greater endogenous estrogen exposure is associated with longer telomeres in postmenopausal women at risk for cognitive decline. Brain Res 1379, 224-231.
46. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women:Women's Health Initiative Memory Study. JAMA 291, 2947-2958. (Pubitemid 38802684)
47. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol 66, 300-305.
48. Fujiwara Y, Takahashi M, Tanaka M, Hoshi T, Someya T, Shinkai S (2003) Relationships between plasma beta-amyloid peptide 1-42 and atherosclerotic risk factors in communitybased older populations. Gerontology 49, 374-379. (Pubitemid 37465117)
49. Korf ES, White LR, Scheltens P, Launer LJ (2004) Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 44, 29-34. (Pubitemid 38823483)
50. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350, 757-764. (Pubitemid 27387202)
51. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM (2007) Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 117, 3393-3402. (Pubitemid 350096995)
52. Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, Bochynska A (2003) The effect of cholinesterase inhibitors on the regional blood flowin patients with Alzheimer's disease and vascular dementia. J Neurol Sci 216, 119-126. (Pubitemid 37371876)